新京报讯 据“北京通州发布”微信公众号消息,副中心企业有大突破!5月14日,中关村通州园企业甘李药业发布公告称,其产品赖脯胰岛素注射液已正式获得欧盟委员会(EC)上市批准。据悉,这是继甘精胰岛素注射液、门冬胰岛素注射液之后,该企业在半年内在欧洲市场获批的第三款胰岛素产品。至此,这家副中心企业成为中国首家,也是目前唯一一家在欧盟获批长效、速效胰岛素的制药企业,是首个在欧盟实现三款三代胰岛素产品获批的...
Source Link新京报讯 据“北京通州发布”微信公众号消息,副中心企业有大突破!5月14日,中关村通州园企业甘李药业发布公告称,其产品赖脯胰岛素注射液已正式获得欧盟委员会(EC)上市批准。据悉,这是继甘精胰岛素注射液、门冬胰岛素注射液之后,该企业在半年内在欧洲市场获批的第三款胰岛素产品。至此,这家副中心企业成为中国首家,也是目前唯一一家在欧盟获批长效、速效胰岛素的制药企业,是首个在欧盟实现三款三代胰岛素产品获批的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.